Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia

Summary

Congenital hyperinsulinism is a rare condition that can cause life-threatening hypoglycemia. Current treatment for congenital hyperinsulinism is often suboptimal, and such individuals may respond to a new somatostatin analog, pasireotide. This is a compassionate use study of the effects of pasireotide on individuals with suboptimally treated congenital hyperinsulinism.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications